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ABSTRACT
Influenza is a segmented negative strand RNA virus. Each RNA segment
is encapsulated by viral nucleoprotein (NP) and bound by the viral RNA
dependent RNA polymerase (RdRP) to form viral ribonucleoproteins (vRNPs)
responsible for RNA synthesis. NP is a structural component of the vRNP but
also interacts with both viral and host factors to regulate viral RNA expression.
NP is conserved among influenza A isolates, making NP interactions compelling
antiviral targets. Here I characterize mutations within 5 amino acids of NP that
comprise an accessible region of the NP body domain, as determined by NP
crystal structure. This region was selected for mutagenesis to target interaction
between NP and RdRP.
NPbd3 encodes glycine at 5 amino acids within the accessible NP body
domain. Cellular fractionation and Western Blot, in addition to NP-GFP fusions
and fluorescence, confirm NPbd3 was expressed and localized as WT-NP. Gel
shift with purified NP protein confirm NPbd3 bound nucleic acids as WT-NP.
Although NPbd3 was expressed, localized, and bound nucleic acid as WT-NP, I
found NPbd3 was defective for RNA expression in reconstituted vRNPs, as
evaluated by reverse transcription and quantitative polymerase chain reaction
(RT-qPCR). To investigate this NP body domain further, single and double amino
acid mutations were cloned. Analysis of NP single mutants revealed that all were
nearly as functional as WT-NP for RNA expression in reconstituted vRNPs,
suggesting these accessible amino acids in the NP body domain play a
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redundant role. However, four different combinations of two amino acid mutations
resulted in NP double mutants that displayed a significant defect in RNA
expression in reconstituted vRNPs, confirming these accessible amino acids in
the NP body domain play a significant role for viral RNA synthesis.
A disruption in an essential NP interaction with the RdRP is likely the
explanation for the RNA defect observed. In support of this, avian influenza virus
passaged in human cells resulted in virus with one NP amino acid change in this
domain consistently paired with specific changes in the PB2 subunit of the RdRP.
I reason this accessible body domain of NP is a viable antiviral target. Indeed,
two amino acids in this NP body domain comprise a novel groove implicated in
binding the small molecule inhibitor nucleozin. My thesis highlights this
conserved NP body domain as an important interaction surface essential for viral
RNA synthesis and support further investigation of antiviral drugs that target this
region of NP.
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CHAPTER ONE
EMERGING ANTIVIRAL RESISTANT STRAINS OF INFLUENZA A AND THE
POTENTIAL THERAPEUTIC TARGETS WITHIN THE VIRAL
RIBONUCLEOPROTEIN (VRNP) COMPLEX

Background
This chapter is copied in whole from Davis et al.: Emerging antiviral resistant
strains of influenza A and the potential therapeutic targets within the viral
ribonucleoprotein (vRNP) complex. Virology Journal 2014 11:167.
Influenza A viruses are infectious agents spread through contact or
aerosol droplets that result in a seasonal respiratory illness which can potentially
lead to death. Highly transmissible influenza A viruses can reach pandemic
proportions as seen in 1918, 1957, 1968, and 2009. The natural reservoir for
influenza A viruses are aquatic birds, but many animals are susceptible to
infection, including swine and humans. While humans are not readily infected
with avian influenza viruses, in rare cases direct avian to human transmission
has occurred. Swine are readily susceptible to avian, swine, and human
influenza subtypes and provide a vessel for genome reassortment among
different subtypes of the virus. The influenza A virus genome is made up of eight
negative sense RNA segments (vRNA). Reassortment of genome segments
between different influenza A subtypes can yield new influenza A subtypes that
have potential to cause a human influenza pandemic. While the 1918 pandemic
virus was found to be of wholly avian origin, the 1957 and 1968 pandemics
1

contained segments of avian and human origin (Reid and Taubengerger, 2003).
In this case it is unclear if swine or human were the vessel of reassortment;
although swine are more readily infected with avian influenzas, thus providing
more opportunity for reassortment, humans can be infected with avian influenza,
and although rare, reassortment within a human host remains a possibility (Reid
and Taubengerger, 2003). The 2009 influenza H1N1 pandemic contained
segments of avian, swine, and human origin and was thus a triple reassortant
that likely emerged from swine (Neumann et al., 2009).
Influenza infection is typically prevented by annual vaccination. However,
vaccines are not useful after infection or against emerging subtypes of influenza
not targeted during vaccine production, as witnessed with the novel H1N1
pandemic in 2009. Therefore, antivirals that target specific proteins to inhibit virus
replication are necessary to stave the spread of an emerging pandemic. The
eight genome segments of influenza A virus encode 10 different coding mRNAs
by way of alternate splicing (Dubois et al., 2014) which result in over 12 proteins
due to alternate translation (Chen et al., 2001, Wise et al., 2009, Jagger et al.,
2012, Muramoto et al., 2012). Two viral segments code for the surface proteins
HA and NA for which influenza subtypes are named. Three viral gene segments
encode the RNA dependent RNA polymerase complex: PA, PB1, and PB2. At
least two of these genome segments also encode alternate translation products
including PB1-F2, PB1-N40, PA-X, PA-N155 and PA-N182 (Chen et al., 2001,
Wise et al., 2009, Jagger et al., 2012, Muramoto et al., 2012). One segment
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encodes the nucleoprotein NP. Two segments, M and NS, undergo alternate
splicing to produce NS1, NS2 (NEP), M1 and M2 proteins. With so many viral
protein interactions required in various stages of the influenza life cycle, there are
numerous potential target sites for antiviral treatments. Current antivirals target
the activities of M2 and NA, but resistance is emerging. This review catalogs the
current state of influenza antiviral resistance and describes promising new
molecules targeting proteins within the viral ribonucleoprotein (vRNP), the
complex comprised of the viral RNA genome, the RNA-dependent RNA
polymerase (RdRP), and nucleoprotein (NP).
Current Antivirals and Resistance
The current antivirals approved by the FDA are, in order of their release,
Symmetra (amantadine), Flumadine (rimantadine), Relenza (zanamivir), and
Tamiflu (oseltamivir). Amantadine and rimantandine are adamantane derivatives
that target and inhibit the M2 ion channel. The M2 ion channel is an integral
membrane protein responsible for release of vRNPs during infection (Pinto et al.,
1992). By binding to the M2 ion channel, amantadine and rimantandine inhibit
vRNP release and thus viral replication (Hay et al., 1985, Jing et al., 2008). The
antivirals zanamivir and oseltamivir are NA or neuraminidase inhibitors. NA
activity is required to release new virions from infected cells (Davis et al., 1983).
These drugs inhibit virus release from infected host cells by binding to the active
site of the NA protein (Meindl et al., 1974, Palese and Compans, 1974).
Resistance against both classes of influenza antiviral treatments has been

3

documented. Resistance to M2 ion channel inhibitors occurs via a triple amino
acid deletion at residues 28-31 or single amino acid substitutions in the
transmembrane region spanning residues 26-31 of the M2 protein (Holsinger et
al., 1994, Abed et al., 2005). 100% of H3N2 influenza A viruses circulating in
2009-2010 and 99.8% of 2009 pandemic H1N1 were resistant to adamantanes
(CDC-1). Many resistant H1N1 isolates encoded V27A substitution, while
resistant H3N2 isolates were found to encode substitutions at L26F, V27A, A30T,
S31N, or G34E (Tang et al., 2008). Resistance to adamantanes in H7N9 has
also been documented and is acquired by substitution S31N (Chen et al., 2013).
Resistance to NA inhibitors is less common as this class of inhibitors was
developed later. For example, 98.9% of tested 2009 H1N1 viruses remained
susceptible to oseltamivir, 100% of 2009 H1N1 viruses tested remained
susceptible to zanamivir (CDC-2), 100% of influenza A (H3N2) tested remained
susceptible to both oseltamivir and zanamivir for the 2012-2013 season (CDC-3).
However, multiple single amino acid changes in NA alter susceptibility to the
approved neuraminidase inhibitors. Residues V116, I117, E119, Q136, K150,
D151, D199, I223, H275, and N295 were selected to monitor for changes that
confer drug resistance or reduce efficacy of the antivirals (Deyde et al., 2010).

Resistance evolves during treatment, via single amino acid substitutions
including changes to amino acids mentioned above such as E119V I223R
(Pizzorno et al., 2012, van der Vries et al., 2011), and H275Y (Baz et al., 2009),
but also R292K and N294S (Kiso et al., 2004). Pandemic H1N1 2009 isolates
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with a substitution at I223R were resistant to neuraminidase inhibitors in addition
to M2 ion channel inhibitors as discussed above (van der Vries et al., 2011).
Thus, while NA inhibitors are currently still viable to combat most emerging
influenza threats, it is only a matter of time before resistance takes hold as with
the adamantanes, rendering both current antiviral therapies ineffective against an
emerging influenza threat.
Most worrisome is resistance reported among Highly Pathogenic Avian
Influenza (HPAI) subtypes that could spur the next pandemic. Avian subtypes
such as H5N1, H7N9, and H7N7 have all resulted in human infection. The H5N1
infections result in high morbidity at ~60%, while H7N9 and H7N7 have seen
more variability in outcome of human infection (WHO). Fortunately none of these
subtypes have gained the ability to transmit readily from human to human, but
unfortunately, these strains already have antiviral resistant isolates reported. For
example, all H7N9 isolates tested were resistant to adamantanes via the S31N
substitution in the M2 protein (Gao et al., 2013), while some H7N9 exhibit high
resistance to oseltamivir, mid-resistance to peramivir, and low-resistance to
zanamivir via the NA R292K substitution (Hai et al., 2013). Also of grave concern
are H5N1 isolates that encode M2 changes to confer resistance to adamantanes
and NA changes that reduce susceptibility to neuraminidase inhibitors (Hurt et
al., 2007). With many circulating antiviral resistant strains and the consequences
of a looming virulent influenza pandemic, novel antiviral targets must be
investigated so that new therapies can be developed before such a catastrophic
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event occurs. One promising new viral target is the viral ribonucleoprotein or
vRNP. Figure 1 depicts vRNP interactions and activities targeted by new antiinfluenza candidates.

VRNP: Viral Ribonucleoprotein
During infection eight vRNPs, containing the eight different vRNA genome
segments, are released and imported into the nucleus to transcribe and replicate
the vRNA. Transcription of the viral genome proceeds via a cellular cappedmRNA primer cleaved from host mRNA by the viral polymerase (Plotch et al.,
1981). Unlike other RNA genome viruses, which typically replicate in the
cytoplasm, influenza must enter the nucleus to steal nascent host capped
mRNAs for use as primers in transcription. The polymerase subunit PA provides
the endonuclease activity (Yuan et al., 2009, Dias et al., 2009), while PB2
houses the active site where the host pre-mRNA will bind (33). Polymerization of
the viral mRNA transcript proceeds via the PB1 subunit until the polyadenylation
signal of repetitive U residues result in stuttering by the viral RdRP and yields the
poly(A) tail, terminating transcription (Poon et al., 1999). Transcripts of two
influenza genome segments, M and NS, undergo alternative splicing to produce
M1, M2, NS1 and NS2 (NEP); utilization of host nuclear splicing machinery is
another reason for nuclear localization of influenza vRNPs.
Viral replication occurs de novo, without a primer (Shapiro et al., 1988). In
the host cell viral RNA replication occurs after translation of viral RdRP and NP
proteins. Evidence suggests a model wherein the resident RdRP of the vRNP is
6

responsible for transcription, while a soluble RdRP is responsible for replication
from the vRNA template (Jorba et al., 2009). There are two primer-independent
steps of viral replication. First the vRNA template is used to synthesize a fulllength complementary (cRNA), which is then replicated to yield progeny vRNA
that can be transcribed to mRNA or packaged into new virions during later stages
of the viral replication cycle. NP is required for anti-termination at the poly U
stretch to allow for replication of full length cRNA (Beaton and Krug, 1986). NP
encapsidates both cRNA and vRNA replication products and is necessary for
genome length functional cRNPs and vRNPs, respectively (Honda et al., 1988).
NP: Nucleoprotein
The crystal structure of NP (Ye et al., 2006) (Figure 2) reveals two regions
termed the body domain and the head domain, between which lies a deep
groove comprised of positively charged basic amino acid residues that form ionic
bonds with the negatively charged phosphate backbone of viral cRNA and vRNA.
On the opposing side of the RNA binding groove lies a tail loop for
oligomerization with other NP monomers. The tail loop of NP spans residues
402-428, and is critical to NP oligomerization and RNA binding, as shown
through a tail loop deletion mutant that produced primarily monomeric NP unable
to oligomerize and bind RNA (Ye et al., 2013). Another crucial oligomerization
interaction occurs through a salt bridge between residue 339 of one NP
monomer and residue 416 of another NP monomer (Ye et al., 2006, Kao et al.,
2009, Shen et al., 2011). Mutational studies disrupting this salt bridge led to
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inhibition of viral RNA synthesis in vitro, further highlighting the importance of the
interaction between NP molecules for vRNP function (Shen et al., 2011).
However, NP is more than a structural RNA binding protein. NP
associates with viral proteins such as PB1 and PB2 (Biswas et al., 1998), and M1
(Avalos et al., 1997), in addition to several cellular factors (Portela and Digard,
2002). Interaction between NP and the RdRP enhanced unprimed replication in
vitro, suggesting the NP-RdRP interaction may regulate the switch from primer
initiated transcription to unprimed replication (Newcomb et al., 2009). Interaction
of NP with the polymerase subunits was crudely mapped to regions within both
the body and head domain of the NP crystal structure (Biswas et al., 1998, Ye et
al., 2006). NP-PB2 and NP-PB1 associations were confirmed through coimmunoprecipitation assays in the absence of other viral factors (Biswas et al.,
1998). The NP-PB2 interaction was refined to residue 627 and 630 of PB2 and
residue 150 of NP, with the strength of NP-PB2 interaction directly correlated
with RdRP activity (Ng et al., 2012). Residue R150 of NP is highly conserved and
vital for normal viral RNA synthesis during influenza A WSN infection of MDCK
cells (Li et al., 2009). As discussed below, PB2 residue 627 is a wellcharacterized host range determinant (Subbarao et al., 1993, Kuzuhara et al.,
2009). Additional NP mutational analysis revealed alanine substitutions within
three residues of the head domain at 204, 207, and 208 disrupt interaction with
the viral polymerase and inhibit viral RNA synthesis (Marklund et al., 2012).
Cryo-EM and cryo-electron tomography data of native vRNPs in packaged
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virions revealed two different conformations of polymerase interaction with NP
within the vRNP (Arranz et al., 2012). Together, the evidence points to multiple
residues on NP that participate in NP-RdRP interactions. The protein sequence
homology of NP is a staggering ninety percent among influenza A isolates
(Gorman et al., 1990), with the described interaction domains exhibiting even
greater homology, highlighting the potential of disrupting NP interactions as an
effective antiviral target.
RdRP: RNA Dependent RNA Polymerase
The influenza A virus RNA dependent RNA polymerase is a heterotrimer
comprised of PA, PB2, and PB1.
PA. While PA is required for both viral transcription and replication, the
major role attributed to PA during influenza infection is the endonuclease activity
needed to steal capped primers for viral transcription initiation in the nucleus of a
host cell (Plotch et al., 1981, Yuan et al., 2009, Dias et al., 2009, Zhao et al.,
2009). Several highly conserved endonuclease active sites span the N-terminal
209 residues of PA (Dias et al., 2009). Alanine screening of amino acids 102
through 134 revealed residues necessary for endonuclease activity (Hara et al.,
2006). Substitutions D108A and K134A individually inhibited both endonuclease
activity and transcription in vitro (Yuan et al., 2009, Hara et al., 2006). PA also
makes contacts with both vRNA and cRNA promoters between residues 100180, though the precise residues involved are debated (Hara et al., 2006, Deng
et al., 2006, Maier et al., 2008). In addition, PA has documented protease activity
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with Ser 624 defined as the active site (Hara et al., 2006), though the purpose of
this activity remains poorly understood. The essential endonuclease activity of
PA is an excellent target for antivirals.
PB2. PB2 contains the cap-binding domain, which recognizes the capped
structure on nascent host mRNAs to be cleaved by the endonuclease site of PA
(Li et al., 2001). PB2 residues 318-483 comprise this domain and contain two
aromatic amino acids at positions 363 and 404 necessary for cap-binding
(Fetcher et al., 2003, Guilligay et al., 2008). The cap-binding domain of PB2 may
also mediate interaction between PB1 and PB2, specifically a loop consisting of
residues 421-427 of PB2, which is essential for cap-dependent transcription but
not cap-binding, as determined by a deletion mutant (Guiligay et al., 2008). Capbinding and capped RNA primed transcription are essential activities for influenza
that can be targeted by novel antivirals.
PB2 also makes contacts with both vRNA and cRNA promoters in an
alpha helix rich region between residues 535-684, which form an RNA binding
domain (Kuzuhara et al., 2009). Located within this domain is residue 627, a
well-characterized species and pathogenicity determinant for influenza A viruses
(Subbarao et al., 1993, Kuzuhara et al., 2009, Massin et al., 2001, Shinya et al.,
2004, Labadie et al., 2007, Tarendeau et al., 2008). Avian influenza A viruses
encode PB2 with glutamic acid at residue 627, while human influenza A viruses
encode lysine (Subbarao et al., 1993). RNA binding ability of PB2 was linked to
the amino acid encoded at 627, with increased RNA binding shown for PB2

10

proteins containing 627K (Kuzuhara et al., 2009). Polymerase activity and
interaction of PB2 with NP were also shown to be influenced by PB2 residue 627,
in addition to residue 630 (Ng et al., 2012). Characteristic avian PB2 residue
E627 must also encode R630 for proper polymerase activity and coimmunoprecipitation with NP (Ng et al., 2012). Characteristic human PB2 residue
K627 requires G630 for proper polymerase activity and co-immunoprecipitation
with NP (Ng et al., 2012). Residue 627 of PB2 influences binding of NP and
RNA, two interactions essential for viral RNA synthesis, making this region of
PB2 a favorable target for new antivirals.
PB1. PB1 is the RNA polymerizing subunit of the RNA dependent RNA
polymerase. Residues 1-83 and 494-757 of PB1 contribute to vRNA template
interaction through in vitro analysis of PB1 deletion mutants (González et al.,
1999). PB1 interacts with PA through its N terminal domain and PB2 through its
C terminal domain, thus forming the functional RNA dependent RNA polymerase
(Perez and Donis, 1995, González et al., 1996, Perez et al., 2001, He et al.,
2008). RNA dependent RNA polymerase activity of RNA viruses represents a
viral activity that can be targeted by antivirals.
The C-terminal domain of PB1 (678-757) and the N-terminal domain of
PB2 (1-37) were defined as the regions responsible for PB1-PB2 interaction and
were crystalized to facilitate further investigation (González et al., 1996,
Sugiyama et al., 2009). Crystal structure of this interaction reveals all contacts
occur through helix 1 of PB2 (residues 1-12), which is essential for proper RNA
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polymerase activity (Sugiyama et al., 2009). The PB1-PB2 protein interface is of
great interest as an antiviral target due to the conservation of these domains in
both human and avian viruses (Sugiyama et al., 2009).
The N-terminus of PB1 (1-80) interacts with the C terminal region of PA
consisting of residues 239-716 (González et al., 1996, Krug and Aramini, 2009).
Interaction surfaces of both PB1 and PA are highly conserved (He et al., 2008,
Wunderlich et al., 2009, Obayashi et al., 2008). The crystal structure of this
interaction reveals PB1 N terminal 25 residues occupy a C-terminal hydrophobic
groove of PA (68) (Figure 3). The C-terminal domain of PA has been referred to
as a “dragon’s head” that holds the N-terminus of PB1 in its “jaws” (He et al.,
2008). A peptide analog of the N-terminal 25 amino acids of PB1 blocks
formation of the RNA dependent RNA polymerase complex resulting in no viral
replication (He et al., 2008, Ghanem et al., 2007). These studies demonstrate the
critical interaction between PB1 and PA in the formation of the RNA dependent
RNA polymerase heterotrimer vital for viral RNA synthesis, making this
interaction a potential target for novel antivirals.

New Antivirals Targeting Influenza A VRNP
The critical roles of the influenza vRNP for viral RNA synthesis make
activities of the vRNP, such as cap-snatching and RNA polymerization, excellent
antiviral targets. A recently discovered nucleotide analog preferentially utilized by
viral RNA dependent RNA polymerases including influenza vRNP, is under study
as a promising antiviral therapy targeting the activity of viral RNA dependent
12

RNA polymerases (Furuta et al., 2002). Further, the multiple essential
interactions of the vRNP, such as with each other to form the RNA dependent
RNA polymerase heterodimer, with host capped mRNAs to obtain primers for
viral transcription, and with NP to regulate and enhance RNA replication, coupled
with high conservation of these domains among influenza subtypes, make the
proteins of the vRNP excellent targets for small molecule inhibitors with broad
efficacy against multiple influenza A subtypes.
Ribonucleotide Analogs
Favipiravir is a 6-fluoro-3-hydroxy-2-pyrazinecarboxamide molecule (also
known as T-705) that upon phosphorylation becomes favipiravir-ribofuranosyl-5’triphosphate (RTP) and inhibits many viral RNA dependent RNA polymerases
(75). Favipiravir is effective against influenza A, influenza B, influenza C,
hantaviruses, flaviviruses, noroviruses, and most recently ebola viruses (Furuta
et al., 2002, Furuta et al., 2013, Oestereich et al., 2014). The T-705 RTP is
erroneously interpreted as a purine nucleotide by the viral polymerase during
RNA elongation (Furuta et al., 2013, Jin et al., 2013). Once incorporated into the
elongating viral RNA, the analog may hinder strand extension (Jin et al., 2013).
The antiviral activity of Favipiravir includes influenza A(H3N2), A(H1N1),
A(H5N1), A(H7N9), and strains bearing resistance to both classes of the current
FDA approved influenza antivirals (Furuta et al., 2002, Furuta et al., 2013,
Sleeman et al., 2010).
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The 50% inhibitory concentration (IC50) of favipiravir for influenza,
determined by plaque reduction assay, was 0.013-0.48 µg/ml with no cytotoxic
effect up to 1000 µg/ml (Furuta et al., 2002). Human DNA polymerase α, β, or γ
with 1000 µM of favipiravir showed little sign of inhibition (Kiso et al., 2010) and
human RNA polymerase II had an IC50 of 905 µM of favipiravir (Takahashi et al.,
2011). Therefore, the IC50 of host polymerases is well over 2000 times greater
then the IC50 for influenza vRNP, making favipiravir highly selective for influenza
vRNP (Furuta et al., 2013). Favipiravir for influenza therapy has finished two
Phase II clinical trials in the United States and one Phase II clinical trial in Japan
(Furuta et al., 2013). Favipiravir is a favorable candidate for a broadly effective
antiviral therapy targeting RNA viruses with RNA dependent RNA polymerases
that preferentially incorporate favipiravir in RNA synthesis. It is not yet clear if or
how quickly influenza vRNP will evolve resistance to this nucleotide analog, but
based on HBV and approved nucleotide analog therapies (Menéndez-Arias et al.,
2014), as with any antiviral therapy, if resistance is possible, it will eventually
develop, stressing the need to consistently look for novel antiviral targets and
therapies.
Small Molecule Inhibitors
Unlike nucleotide analog therapies, small molecule inhibitors work by
interaction with a viral protein to block a function or interaction and inhibit viral
replication. Crystal structure data provides much information to identify small
molecules with potential to bind a domain of the target protein and inhibit
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essential functions or interactions. Small molecules that target conserved regions
are likely to have the best efficacy against multiple subtypes. Further, conserved
regions are less likely to tolerate mutation and evolve a viable virus with
resistance to the small molecule.
Targeting NP
Nucleozin is a small molecule inhibitor of NP that works by promoting NP
oligomerization, blocking nuclear entry through aggregation of NP molecules at
the nuclear membrane (Kao et al., 2010) and inducing vRNP aggregation during
cytoplasmic trafficking (Amorim et al., 2013). Molecular docking models identified
two proposed nucleozin interaction sites at residue 289 and 309 of NP (Kao et
al., 2010). Both residues participate to stabilize the interaction; a tyrosine at
residue 289 forms aromatic ring stacking with nucleozin, while an asparagine at
residue 309 shares a hydrogen bond with nucleozin. Strains found to be
nucleozin resistant encoded a histidine in place of a tyrosine at residue 289 of
NP (Kao et al., 2010). From the crystal structure of NP, residue 289 is relatively
accessible to interact with nucleozin (Figure 2) (39, Kao et al., 2010). The 289H
NP variant likely disrupts a critical point of interaction between NP and nucleozin.
Sequence analysis of the NP gene of 3,881 influenza strains revealed Y289H
substitution in 527 strains. Unfortunately the A(H1N1)pdm09 strain was shown to
contain this single amino acid alteration, signifying it as a nucleozin resistant
strain (Kao et al., 2010). Nucleozin demonstrated a 50% effective concentration
(EC50) of only 0.069 µM against influenza with 50% cytotoxic concentration
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greater than 250 µM (Kao et al., 2010). Thus nucleozin still holds potential as a
potent antiviral for strains of influenza housing a tyrosine at residue 289 (Kao et
al., 2010). In addition to nucleozin, there are several other aryl piperazine amide
compounds discovered in parallel that target NP and inhibit virus replication in
the same manner (Kao et al., 2010, Su et al., 2010, Gerritz et al., 2011, Cianci et
al., 2013). Cianci et al. provide a detailed review into the efficacy of aryl
piperazine amides, including nucleozin, as NP inhibitors (Cianci et al., 2013).
Further analysis of these compounds could lead to the synthesis of an optimized
aryl piperazine amide inhibitor of viral replication, even against the circulating
nucleozin resistant strains of influenza.
The essential salt bridge for NP oligomerization at residues 339 and 416
was targeted for disruption by small molecule inhibitors (Figure 2) (Shen et al.,
2011). Peptides that mimicked the NP tail loop (residues 402-428) bound in the
tail loop binding pocket and inhibited NP oligomerization, resulting in decreased
viral replication by greater than fifty percent (Shen et al., 2011). Random virtual
screening of small molecules identified four compounds (termed # 3, 7, 12, and
23) that interrupt NP oligomerization and decrease viral replication (Shen et al.,
2011). The IC50 of compounds 3, 7, 12, and 23 ranged from 2.4 to 118 µM in
cells challenged with influenza A/WSN/33 for nine hours at a multiplicity of
infection (MOI) of 0.2 (Shen et al., 2011). Although the targeted NP domain is
highly conserved, more research will need to be carried out to ensure little to no
development of resistance to the compounds. Importantly, cytotoxicity of these
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compounds will need to be assessed before they can be of use as antiviral
therapies.
Mycalamide A is an antiviral and antitumor compound isolated from
Mycale sponges but is unfortunately toxic to cells (Perry et al., 1988). A photocross-linked chemical array identified analogs of mycalamide A that possess the
ability to bind NP (Hagiwara et al., 2010). One compound inhibited viral
replication up to 77% in a plaque assay using influenza virus (A/WSN/33) with no
cytotoxic effect (Hagiwara et al., 2010). Binding affinity of the analogs was
greatest within the N-terminal 110 amino acids of NP (Hagiwara et al., 2010).
Although the mechanism of inhibition remains uncharacterized, the N-terminus of
NP contains an important non-canonical nuclear localization signal (NLS) (Wang
et al., 1997, Cros et al., 2005) and interacts with host RNA processing factors
UAP56 and URH49 (Momose et al., 2001, Wisskirchen et al., 2011) proposed to
enhance RNA replication (Kawaguchi et al., 2011). More research is needed on
these compounds to elucidate the mechanism of inhibition and determine if or
how quickly influenza NP will evolve resistance.
Naproxen is an over the counter nonsteroidal anti-inflammatory drug that
inhibits NP from associating with RNA in the RNA binding groove (Figure 2)
(Lejal et al., 2013). From several molecular docking studies, residues Y148,
Q149, R150, R355, R361, and F489 are believed to stabilize naproxen binding to
NP (Lejal et al., 2013). Naproxen acts selectively upon monomeric NP and was
shown to protect MDCK cells and mice from a viral challenge at an MOI of 10-2 -
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10-3 or 50 - 2,000 PFU respectively, with little to no cytotoxic effects (Lejal et al.,
2013). Subtypes of H1N1 and H3N2 were both susceptible to inhibition and
treatment resulted in efficient protection from viral challenge with either subtype
(Lejal et al., 2013). No escape mutant viruses were produced in response to 500
µM naproxen treatment in cells after six passages (Lejal et al., 2013). Within this
experiment the mode of delivery for naproxen was intraperitoneal injection or
intranasal treatment in mice that displayed an EC50 of 40mg/kg (Lejal et al.,
2013). Naproxen is currently used as an oral medication with a recommended
dosage of 220 mg every 8 hours for pain. Naproxen is not currently used as an
antiviral but could be optimized for antiviral use through further experimentation
and improved drug design.
Targeting PA-PB1 Interaction
Inhibitors of the PA-PB1 interaction are numerous (Muratore et al., 2012).
Compound 1 was discovered through in silico screening (Muratore et al., 2012)
using the crystal structure of PAC-PB1N (Figure 3) (He et al., 2008). The
hydrophobic pocket of PA houses compound 1 according to molecular docking
studies, and inhibition of PA-PB1 interaction was demonstrated through ELISA
and immunoprecipitation of PA (Muratore et al., 2012). Compound 1 inhibited
RNA polymerase activity in a dose-dependent manner with an IC50 of about 18
µM assessed in a minireplicon assay using a firefly luciferase reporter gene, with
no significant cytotoxic effect up to concentrations of 250-1000 µM (Muratore et
al., 2012). Compound 1 inhibited viral replication in MDCK cells for several
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influenza A H1N1 and H3N2 strains, a swine-origin influenza virus, and an
oseltamivir-resistant isolate, with IC50 ranging from 12.2 to 22.5 µM (Muratore et
al., 2012).
There are two FDA approved medications that in addition to their intended
use also possess anti-IAV abilities due to their structural similarity with the N
terminal domain of PB1 that interacts with the C-terminus of PA (Figure 3)
(Fukuoka et al., 2012). Benzbromarone is approved to treat gout and
hyperuricemia by promoting the excretion of uric acid. Diclazuril is most
commonly used in veterinary medicine as an anti-coccidial. Although these drugs
are FDA approved, appropriate drug dosages for use against viral challenges
would need to be established before they could be employed for use against
influenza A. Testing for the ability of viruses to gain resistance to these drugs
must also be done. Benzbromarone and diclazuril could potentially be utilized if
an influenza strain arises that possesses resistance to other antivirals available
(Fukuoka et al., 2012).
In addition, a compound derived from licorice, 18β-glycyrrhetinic acid
(GHA), is a naturally occurring compound that exhibits some anti-IAV activity
attributed to interaction with the C terminal domain of PA (Li et al., 2012).
Molecular docking studies identified GHA as a ligand to PAC (Li et al., 2012).
GHA decreased polymerase activity 80%, as assessed by a primer extension
assay for cRNA synthesis (Li et al., 2012). These preliminary findings need to be
investigated further with more informative assays including in vitro PA-PB1
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interaction inhibition study, in vivo polymerase activity assays in tissue culture,
and in vivo infection in an animal model. There are many small molecules that
mimic the N terminus of PB1 fit in the hydrophobic groove of PA to inhibit PAPB1 interaction (Figure 3) and should be studied further for their potential as an
anti-influenza A treatment.
Targeting PA Endonuclease
Fullerene (C60) is a spherical molecule of sixty carbon atoms that exhibits
anti-influenza activity (Shoji et al., 2013). Full length PA and an isolated PA
endonuclease domain were tested in an in vitro endonuclease assay in the
presence of fullerene derivatives. Seven fullerene derivatives were able to inhibit
the endonuclease ability of the full length PA and isolated endonuclease domain
(Shoji et al., 2013). Docking simulations reveal the fullerene skeleton fits nicely
into the endonuclease domain active pocket (Shoji et al., 2013). MDCK cells
were infected with influenza A H1N1 or H3N2 mixed with 0 to 100 µM fullerene
derivative and immunostained for NP at 24 hours post infection to reveal
significantly less NP in cells infected with virus pre-incubated with fullerene
compared to a DMSO control (Shoji et al., 2013). Twelve derivatives of fullerene
were tested and resulted in varying efficacy against influenza but showed no
cytotoxic effect up to 100 µM (Shoji et al., 2013). More investigation into the
activity and expression of viral proteins in response to fullerene needs to be
conducted. Importantly, treatment applied post-infection needs to be
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investigated. This novel compound exemplifies yet another possible antiviral
target within the vRNP.
Targeting PB2 Cap-binding Domain
Compounds that mimic the 7-methylguanosine moiety of the 5’ cap of
mRNAs may serve as transcriptional inhibitors. Docking studies of the capbinding domain of PB2 revealed 7-alkylguanine derivatives as potential inhibitory
compounds (Pautus et al., 2013). Several compounds bind the cap-binding
domain of PB2 with greater affinity than a biotinylated cap analogue (Pautus et
al., 2013). These compounds should be further studied and optimized for antiinfluenza activity.

Conclusion
Influenza A virus continues to remain a human menace, in terms of both
human health and global economic costs. The wide host range of influenza A
virus, coupled with a lack of proofreading activity within the viral RNA dependent
RNA polymerases, and a segmented RNA genome allowing for segment
reassortment, provide influenza A virus with the ability to evolve rapidly. While
yearly vaccination is protective against the strains and subtypes predicted to be
circulating and represented during vaccine production, vaccination will not protect
against an unseen, emerging subtype of the virus. Antivirals are the first line of
defense for an emerging pandemic and resistance to current antivirals is already
circulating within influenza A viruses, hastening the resolve to identify new
antiviral therapies. The viral ribonucleoprotein (vRNP) is essential for viral
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replication, making it an ideal target for antivirals. Essential activities of the vRNP
include cap-snatching activity required for viral mRNA transcription and RNA
polymerase activity required for viral mRNA transcription and RNA replication.
The interactions required to form functional vRNPs with these essential activities
comprise the most highly conserved protein domains within influenza A subtypes.
These interaction domains represent ideal targets for small molecule inhibitors,
as these domains are less likely to tolerate mutations. Combination drug therapy
is also a potential means to challenge emerging antiviral resistance. The vRNP
provides multiple viral protein targets to reduce selection pressures and
emergence of resistant strains. However, if mutations conferring antiviral
resistance are tolerated, history dictates these mutations will be selected by use
of the antiviral and propagate in circulating influenza A viruses. This means the
search for new influenza A antiviral inhibitors should be ongoing until a universal
vaccine is achieved.
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Figure 1. Antiviral Targets of Viral Ribonucleoprotein.
Anti-influenza candidates include small molecule inhibitors that disrupt critical
functions or interactions within the vRNP. This figure provides a summary of the
promising anti-influenza candidates discussed in this review. Davis et al.:
Emerging antiviral resistant strains of influenza A and the potential therapeutic
targets within the viral ribonucleoprotein (vRNP) complex. Virology Journal 2014
11:167.
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Figure 2. Antiviral Targets of Nucleoprotein.
Analysis of NP monomer crystal structure extracted from NP trimer crystal
structure “2IQH” (Ye et al., 2006) using Deep View-Swiss-PdbViewer 4.0.
Residue color determined by accessibility. Greatest to least accessible as
follows: red, orange, yellow, green, light blue, and dark blue. Residue 289 is the
proposed site of interaction with the antiviral compound nucleozin (Kao et al.,
2010). An intermolecular salt bridge formed by residues 339 and 416 of NP is
essential for oligomerization and can be disrupted by small molecule inhibitors
(Shen et al., 2011). Davis et al.: Emerging antiviral resistant strains of influenza A
and the potential therapeutic targets within the viral ribonucleoprotein (vRNP)
complex. Virology Journal 2014 11:167.
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Figure 3. PA-PB1 Interaction Site is an Antiviral Target.
Analysis of the PAC-PB1N crystal structure “3CM8” (He et al., 2008) using Deep
View-Swiss-PdbViewer 4.0. Residues 1–16 of PB1 (red) are shown in interaction
with residues 258–716 of PA (blue). Many small molecule inhibitors of PA
resemble the N terminus of PB1 and bind in the hydrophobic pocket blocking
essential interactions between the polymerase subunits (He et al., 2008,
Ghanem et al., 2007, Fukuoka et al., 2012). Davis et al.: Emerging antiviral
resistant strains of influenza A and the potential therapeutic targets within the
viral ribonucleoprotein (vRNP) complex. Virology Journal 2014 11:167.
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CHAPTER TWO
MUTATIONAL ANALYSIS OF NUCLEOPROTEIN DOMAINS

Identification and Development of Nucleoprotein Mutants
Previous work in our lab investigated potential antiviral targets within NP
by carefully analyzing the protein crystal structure (Ye et al., 2006) to identify
accessible regions. The RNA binding pocket, head domain, and body domain
(Fig. 4) were examined by amino acid substitutions created through cloning. The
RNA binding pocket mutant, NPrbp1, encoded R152A while the head domain
mutant, NPhd1 was altered at amino acids R213A and K214A. Five regions of
the NP body domain were investigated through the following mutants: NPbd1
(E46A, K48A), NPbd2 (D101A), NPbd3 (Y289G, K293G, E294G, Q308G,
N309G), NPbd4 (S482A), and NPbd5 (S467G, E469G, N470G, T471G, and
N472G).

Viral Ribonucleoprotein Activity
Activity of each NP mutant was tested using the reconstituted viral
ribonucleoprotein (vRNP) expression system (Fig. 5). Plasmids to express mRNA
encoding PB1, PB2, PA, and either NP, no NP, or NP mutant, were transfected
into 293T cells along with plasmid to express Green Fluorescent Protein (GFP) M
vRNA, the negative sense vRNA segment of the reconstituted vRNP. GFP
positive cells within this system represent viral gene expression. GFP expression
was observed 48 hours post transfection. All NP mutants expressed GFP at
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similar levels as wild type NP (WT-NP) except NPbd3, the third of five body
domains mutants constructed (Table 1 and Fig. 6). NPbd3 was investigated
further for this master’s thesis.
I next examined the activity of reconstituted vRNPs comprised of NPbd3
at the level of RNA. The defect in viral protein expression observed with NPbd3
is reflected at the RNA level. To directly examine both viral plus sense RNA
synthesis (c/mRNA) and the second step in replication, negative sense RNA
synthesis (vRNA), the reconstituted expression system was carried out with
either an influenza M cRNA or M vRNA template. RNA was isolated from cells,
DNAse treated, reverse transcribed with oligo dT (vRNA template) or vRNA
specific primer (cRNA template), and subjected to qPCR analysis targeting the M
gene. NPbd3 was found to be defective for viral c/mRNA synthesis as compared
to WT-NP (Fig. 7) and vRNA synthesis when compared to the relative expression
of WT-NP (Fig. 7).
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Figure 4. Domains of NP.
Analysis of NP monomer crystal structure (Ye et al., 2006) colored by
accessibility using Deep View-Swiss-PdbViewer 4.0. Greatest to least accessible
as follows: red, orange, yellow, green, light blue, and dark blue.
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PB1
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PA

NP or
Mutant

Figure 5. Reconstituted Ribonucleoprotein Expression System.
pcDNA expression vectors of PB1, PB2, PA, and NP or mutant are transfected
into 293T cells to express RNPs. A pHH21 expression vector containing a
genomic cRNA or vRNA template is also transfected. Cellular RNA polymerase I
drives expression of the cRNA or vRNA template from pHH21. Cellular RNA
polymerase II drives expression of viral mRNAs from pcDNA3 encoding
plasmids.
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Table 1. NP Mutant Analysis.

Seven NP mutants in regions of the RNA binding pocket, body domain, or head
domain were constructed and tested for GFP activity in the reconstituted RNP
expression system. (Laura Newcomb)
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Figure 6. NPbd3 is Defective for Viral Protein Expression.
Plasmids to express reconstituted vRNPs with GFP-M vRNA and either WT-NP,
no NP, or NPbd3 were transfected into 293T cells. 48 hours post transfection
cells were observed for GFP-M expression. WT-NP represents the positive
control while no NP is the negative control. GFP was visualized with a Nikon
Eclipse TS100 (Nikon Intensilight C-HGFI for fluorescence) inverted microscope
and images captured with the Nikon DS-Qi1Mc camera with NS Elements
software.
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Figure 7. NPbd3 is Defective for Viral RNA Expression.
RNA was purified from cells expressing reconstituted vRNPs or cRNPs as
indicated. 1 µg was DNase treated and subject to reverse transcription with oligo
dT and quantitative PCR with gene specific primers to calculate relative M RNA
expression in each sample. Data are from triplicate trials; asterisks indicate
p<0.02.
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CHAPTER THREE
CHARACTERIZATION OF NUCLEOPROTEIN BODY DOMAIN MUTANT #3

Background
The amino acid substitutions in NPbd3 were selected for mutagenesis to
target interaction between NP and RdRP (Biswas et. al., 1998). The amino acids
chosen were based on relative sequence conservation (Fig. 8) and accessibility
in regards to the surface of the protein (Fig. 9) determined by examining the cryoelectron microscopy (cryo-EM) structure of mini-vRNPs (Coloma et. al., 2009)
and NP crystal structure (Ye et. al., 2006). Of seven NP mutants constructed,
NPbd3 was the only mutant to be completely defective for protein expression in a
reconstituted vRNP assay and was also found to be defective in viral RNA
synthesis. These results highlighted the importance of the substituted amino
acids and led to the characterization of NPbd3.

Viral Ribonucleoprotein Activity
Expression and Localization
To ensure NPbd3 was expressed and localized as WT-NP cellular
fractionation and Western blot were performed. Cells were collected and
fractionated using non-ionic detergent and centrifugation as in materials and
methods. Cellular fractions were analyzed by Western blot using anti-FLAG and
anti-Hsp90 antibodies. NPbd3 is expressed and localized as WT-NP (Fig. 10). To
further confirm localization of NPbd3, NP-GFP and NPbd3-GFP fusion proteins
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were constructed and observed through fluorescence microscopy. Again NPbd3
was localized in a pattern similar to WT-NP 48 hours post transfection (Fig. 11).
NPbd3 was expressed at a slightly lower level than WT-NP in many of our
location experiments (Fig. 10). To verify that NP is expressed in excess in the
reconstituted vRNP assay and confirm decreased expression of NPbd3 was not
responsible for the defect observed, we titrated WT-NP expressing plasmid in
transfection from 600 nanograms to 100 nanograms. As expected, lowering
plasmid amount during transfection did result in decreased NP protein
expression (Fig. 12). Titration activity was examined in the reconstituted
expression system using a GFP MvRNA template and confirms that even
transfection of 100ng DNA plasmid resulted in little change in GFP expression
(Fig. 13). While 100ng of NP expression plasmid and 600ng NPbd3 expression
plasmid result in similar NP protein expression (Fig.12), they do not have similar
vRNP activity as represented by GFP expression (Fig. 13). These experiments
confirm NP is in excess in our standard reconstituted vRNP assay and that the
lower NPbd3 expression is not the cause of the lack of activity.
RNA Binding and Oligomerization
NP binds viral RNA and through oligomerization provides the basic
structure for the vRNP. There is one NP monomer for approximately 24
nucleotides of RNA (Ye et. al., 2006). To confirm NPbd3 did not result in a defect
in RNA binding, we performed an electrophoretic mobility shift assay (EMSA).
WT-NP and NPbd3 were immunopurified with FLAG antibody coupled to agarose
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beads. Immunopurified NP proteins were analyzed by SDS-PAGE and
Coomassie Blue stain to ensure no additional protein contaminants (Fig. 14).
Incubation of purified proteins with biotin labeled single stranded nucleic acid
followed by non-denaturing Native PAGE and Western blot with HRPStreptavidin confirmed NPbd3 bound nucleic acids as WT-NP (Fig. 14A). The
Coomassie Blue stain shows a great deal of purified WT-NP but very little NPbd3
(Fig. 14B), which is reflected in the amount of nucleic acid bound. Although there
is a difference in the expression and concentration of protein, we can conclude
NPbd3 binds nucleic acid. Additionally, a preliminary gel shift demonstrated
equal amounts of WT-NP and NPbd3 binding nucleic acid but contained a great
deal of background. NP oligomerization is important for RNA binding and
formation of functional vRNPs. To examine NP oligomer formation, protein
extracts from cells expressing WT-NP or NPbd3 were separated by blue native
polyacrylamide gel electrophoresis (BN-PAGE) followed by western blot with
anti-FLAG antibody. Results demonstrate the ability of WT-NP and NPbd3 to
form oligomers (Fig. 15).
Although NPbd3 was expressed in the cell, localized as WT-NP, found in
oligomers, and bound nucleic acid in vitro, NPbd3 was defective for viral RNA
expression in reconstituted vRNPs and cRNPs. I next decided to further define
the important residues within this domain of NP.
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Figure 8. Sequence Alignment of NPbd3 Residues.
Percent conservation and consensus amino acids of NPbd3 are denoted with
asterisks. Amino acid 289, 293, 294, 308, and 309 are highly conserved in the
influenza strains utilized in the sequence alignment. (Laura Newcomb).
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Figure 9. NP Body Domain Substitutions of NPbd3.
Deep View-Swiss-PdbViewer 4.0 was used to analyze accessible residues in the
body domain of the NP monomer crystal structure (Ye et al., 2006). Residues
289, 293, 294, 308, and 309 were mutated in NPbd3 and are highlighted here.
Residue color determined by accessibility. Greatest to least accessible as
follows: red, orange, yellow, green, light blue, and dark blue.
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Figure 4. NPbd3 is expressed and localized as WT-NP.
WT NP No
NP bd3 NP

Fig. 4A

WT NP No
NP bd3 NP

FLAG
Hsp90

Cytoplasm

Nucleus

Figure 10. NPbd3 is Expressed and Localized as WT-NP.

Fig. 4B

Cells expressing reconstituted vRNPs were collected and fractionated with NP-

DAPI/GFP Merge

40 non-ionic detergent to break open cellular plasma membrane. Microscopy
was used to confirm disrupted plasma membranes and intact nuclei. Nuclei were
pelleted by centrifugation and proteins isolated. Proteins were separated on a
10% SDS PAGE and transferred to nitrocellulose. Western blot was performed
with anti-FLAG to detect WT-NP and NPbd3 and anti-Hsp90 to detect Hsp90, a

WT-NP

NPbd3

eGFP

protein localized in the cytoplasm, which serves as confirmation of cellular
fractionation.
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Figure 11. NPbd3 is Localized as WT-NP.
NP-GFP, NPbd3-GFP, or eGFP were expressed in cells grown on poly-L-Lysine
cover slips. Cells were washed and fixed using a 1:1 methanol and acetone
mixture. The coverslips were mounted onto glass slides using SouthernBiotech™
Dapi-Fluoromount-G™ Clear Mounting Media which stains the cell nucleus blue.
Slides were observed on a Nikon ECLIPSE TE2000-U fluorescent microscope
and images were captured with an Andor Clara DR-3446 camera using NISElements AR software.
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Figure 5. Titration of NP in vRNP
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Figure 12. Low Levels of NP Support Viral Ribonucleoprotein Formation.

g. 5B

Total protein from titration samples was isolated and run on a 10% SDS PAGE
and transferred to nitrocellulose. The membrane was probed with anti-FLAG to
identify NP and anti-Tubulin as the loading control.

WT-NP
600 ng

WT-NP
400 ng

WT-NP
200 ng

WT-NP
100 ng

40

No NP

NPb
600

Figure 13. NP Titration Displays Activity at Lower Plasmid Concentration.
Plasmids to express reconstituted vRNPs with GFP-M vRNA and either WT-NP,
no NP, or NPbd3 at the concentrations listed above were transfected into 293T
cells. 48 hours post transfection cells were observed for GFP-M expression. WTNP (400 ng) represents the standard concentration used in our experiments and
positive control while no NP is the negative control. GFP was visualized with a
Nikon Eclipse TS100 (Nikon Intensilight C-HGFI for fluorescence) inverted
microscope and images captured with the Nikon DS-Qi1Mc camera with NS
Elements software.
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Figure 6. NP RNA binding and Oligmerization
Fig. 6A

A#

WT# No## NP#
NP# NP# bd3#

Fig. 6B

B#
WT# No## NP#
NP# NP# bd3#

Figure 14. NPbd3 Maintains Nucleic Acid Binding.
A. WT-NP and NPbd3 were immunopurified using anti-FLAG agarose beads.
Purified WT-NP and NPbd3 were incubated with biotin labeled single stranded
DNA and separated on an 8% PAGE TBE non denaturing gel before transfer to
nitrocellulose. Biotin ssDNA was detected by interaction with Streptavidin-HRP
and ECL reagents. No NP samples serve as the negative control. B.
Immunopurified WT-NP and NPbd3 were run on a 10% denaturing gel and
stained with Coomassie Blue.
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Figure 6. NP RNA binding and Oligmerization.
Fig. 6A

WT# No## NP#
NP# NP# bd3#

Fig. 6B

WT# No## NP#
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Figure 15. NPbd3 Forms Oligomers as WT-NP.
Blue Native Gel Electrophoresis was utilized to migrate protein extracts followed
by western blot with anti-FLAG antibody to demonstrate NP oligomer formation.
(Laura Newcomb and Jose Ramirez).
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CHAPTER FOUR
NUCLEOPROTEIN BODY DOMAIN SINGLE MUTANT ANALYSIS

Background
To investigate the NP body domain further, single amino acid glycine
substitution mutants were cloned, Y289G, K293G, E294G, Q308G, and N309G.
This method was conducted to conclude whether a single amino acid substitution
was solely responsible for the defect observed in NPbd3.

Viral Ribonucleoprotein Activity
Single amino acid mutants were analyzed for vRNP function by assessing
GFP expression using our reconstituted vRNP expression system with GFP-M
vRNA (Fig. 5). All five single NP mutants displayed activity similar to WT-NP (Fig.
16). Protein analysis showed the NP single mutants were expressed at levels
similar to WT-NP (Fig. 17). RNA analysis of the M gene through reverse
transcription using oligo-dT primers and qPCR revealed levels of viral mRNA
expression with no statistical difference compared to WT-NP (Fig. 18). Therefore,
our analysis of NP single substitutions within this region of the body domain
revealed that all were nearly as functional as WT-NP, suggesting these
accessible amino acids play a redundant role.
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Figure 7. NP body domain single amino acid mutants display near wild type
activity in vRNP assay.
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vRNA template and WT-NP, no NP, or NP mutant. Total protein extract was
separated on 10% SDS PAGE and transferred to nitrocellulose. WT-NP, NPbd3,
and NP single mutants were detected with anti-FLAG. Anti-tubulin was used as
loading control.
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Figure 18. NP Single Mutants Show No Significant Defect in Viral RNA
Expression.
RNA from cells expressing reconstituted vRNPs with FLAG-M vRNA and either
WT-NP, no NP, NPbd3, or the single amino acid NP mutants were isolated. One
microgram of RNA was treated with DNase before being reverse transcribed with
oligo dT (mRNA) and analyzed through qPCR with primers targeting the M gene.
qPCR reactions were carried out in triplicate. Significance was evaluated through
t-test by comparing to WT-NP; asterisks indicate p-values <0.01.
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CHAPTER FIVE
NUCLEOPROTEIN BODY DOMAIN DOUBLE MUTANT ANALYSIS

Background
Single amino acid substitutions within the region of NPbd3 resulted in
functional proteins that acted as WT-NP. These results prompted the creation of
combinational mutations consisting of two amino acid substitutions with the goal
of identifying an NP double mutant with a significant defect in activity.

Viral Ribonucleoprotein Activity
Amino acid pairs were substituted within this region of the NP body
domain to further define which residues contribute to the defect observed. Four
body domain double mutants were constructed, Q308G/N309G, Y289G/E294G,
Y289G/N309G, and K293G/E294G. The pairs of double mutants were designed
based on the relative proximity of the two amino acids to each other using the NP
crystal structure (Fig. 9). These double mutants were analyzed for vRNP function
by assessing GFP expression using our reconstituted vRNP expression system
with GFP-M vRNA (Fig. 5). All NP double mutants showed statistically less GFP
expression than WT-NP (Fig. 19). Total protein analysis by Western blot revealed
that all NP double mutants are expressed as WT-NP (Fig. 20). RNA analysis of
the M gene through reverse transcription using oligo-dT primers and qPCR
revealed a significant decrease in viral mRNA expression in all double mutants
compared to WT-NP (Fig. 21). Analysis of NP double mutants supports the

48

defect in viral RNA expression observed with NPbd3 is likely caused by a
combination of multiple accessible amino acids in the NP body domain.
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Figure 8. NP double amino acid mutants have decreased activity and RNA synthesis.8
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Figure 20. NP Double Mutants are Expressed as WT-NP.

Total protein was isolated from cells expressing reconstituted vRNPs with GFP-M
vRNA template and the indicated NP mutant. Total protein extract was separated
on 10% SDS PAGE and transferred to nitrocellulose. WT-NP, NPbd3, and NP
double mutants were detected with anti-FLAG. Anti-tubulin was used as loading
control.
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Figure 21. NP Double Amino Acid Mutants Show Defect in Viral RNA Expression.
RNA from cells expressing reconstituted vRNPs with FLAG-M vRNA and either
WT-NP, no NP, NPbd3, or the double amino acid NP mutants were isolated. One
microgram of RNA was treated with DNase before being reverse transcribed with
oligo dT (mRNA) and analyzed through quantitative PCR with primers targeting
the M gene. qPCR reactions were carried out in triplicate. Significance was
evaluated through t-test by comparing WT-NP; asterisks indicate p-values <0.02.
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CHAPTER SIX
INTERACTION STUDIES OF NP AND PB2
In order to directly determine NPbd3 interaction with the viral polymerase
co-immunoprecipitation from cellular extracts were performed. Since avian
influenza virus passaged in human cells resulted in virus with one amino acid
change at residue 309 of NP consistently paired with changes in amino acid 627
of the PB2 subunit of the RdRP (Danzy et. al., 2014), we focused our initial
assessment on the NP-PB2 interaction. To facilitate studies with PB2, a Cterminal STREP tagged PB2 protein was constructed through cloning (RameixWelti et al., 2009). The construct was confirmed by sequencing and tested for
activity in a reconstituted vRNP assay (Fig. 22). Additionally a Western blot was
performed to identify the presence of the Strep epitope tag (Fig. 23). Although
the insert of the plasmid was confirmed by sequencing several times, the STREP
antibody never successfully bound to PB2 C-STREP.
An alternative approach was then taken using Anti-FLAG M2 Affinity Gel
agarose beads for immunopurification and a PB2 antibody to assess NP and
PB2 interaction. WT-NP and PB2, 293/294 NP and PB2, WT-NP alone, 293/294
NP alone, and PB2 alone were transfected in to 293T cells (Table 6).
Immunopurified proteins were run on a denaturing gel, transferred to
nitrocellulose and probed with anti-PB2 (Fig. 24). The blot was stripped and also
probed with Anti-FLAG (Fig. 24). When comparing the eluted fraction of WTNP/PB2 and 293/294/PB2 there is less PB2 pulled down in the presence of the
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293/294 NP mutant. The amount of PB2 pulled down and eluted in the 293/294
NP with PB2 sample is similar to the PB2 alone, which serves as a background
control. However, the amount of eluted 293/294 NP mutant is also less than WTNP. No definitive conclusions can be drawn from this trial but this work serves as
preliminary interaction data and demonstrates we should be able to repeat this
assay and obtain conclusive and repeatable results to determine whether or not
NP-PB2 interaction is disrupted with NP mutants within the body domain.
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Figure 22. PB2 C-STREP Activity.
Cells expressing reconstituted vRNPs with WT PB2, no PB2, or PB2 C-STREP
with GFP-M vRNA were visualized for GFP expression with a Nikon Eclipse
TS100 (Nikon Intensilight C-HGFI for fluorescence) inverted microscope and
images captured with the Nikon DS-Qi1Mc camera with NS Elements software.
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Figure 23. STREP Epitope Not Detected in Western Blot.
Total protein was isolated from cells expressing GFP-STREP control protein,
PB2 C-STREP candidates, or vector. Total protein extract was separated on 10%
SDS PAGE and transferred to nitrocellulose. STREP tagged proteins were
detected with anti-STREP.
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Figure 24. Co-Immunoprecipitation of NP and PB2.
Cells expressing WT-NP and PB2, 293/294 NP and PB2, WT-NP alone, 293/294
alone, or PB2 alone were fractionated and immunopurified. Eluate, flow through,
and beads from each sample were run on a 10% SDS PAGE and transferred to
nitrocellulose. The membrane was probed with anti-PB2, stripped, and probed
with anti-FLAG. The three lanes of each sample contain the eluate, flow-through,
and beads (left to right).
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CHAPTER SEVEN
SUMMARY AND DISCUSSION
Mutational analysis of the NP body domain revealed a region of five amino
acids that is essential for viral gene expression. NPbd3 encodes glycine at 5
amino acids within an accessible region of the NP body domain. Cellular
fractionation and Western blot, in addition to NP-GFP fusions and fluorescence,
confirm NPbd3 was expressed and localized as WT-NP (Fig. 10 and 11). Gel
shift (EMSA) with purified NP protein confirm NPbd3 bound nucleic acids as WTNP (Fig. 14). Blue Native Gel Electrophoresis demonstrated NPbd3 oligomerized
(Fig. 15). Although NPbd3 was expressed, localized, and bound nucleic acid as
WT-NP, we found NPbd3 was defective for RNA expression in reconstituted
vRNPs and cRNPs as evaluated by reverse transcription and quantitative
polymerase chain reaction (RT-qPCR).
To investigate this region of the NP body domain further, single and
double amino acid mutations were cloned. Analysis of NP single mutants
revealed that all were nearly as functional as WT-NP for RNA expression in
reconstituted vRNPs, suggesting these accessible amino acids in the NP body
domain play a redundant role (Fig. 18). However, four different combinations of
two amino acid mutations resulted in NP double mutants that displayed a
significant defect in RNA expression in reconstituted vRNPs, confirming these
accessible amino acids in the NP body domain play a significant role for viral
RNA synthesis (Fig. 21). The greatest defect in mRNA synthesis observed was in
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double mutant 293/294, followed by 308/309, 289/309, and 289/294. Although
amino acid 293 is variable and 294 is conserved, a mutation at 294 alone was
not sufficient to cause a defect and the defect observed with 289/294 was only
minimal. In our assays, 294 coupled with a change at 293 resulted in the greatest
observed defect in RNA synthesis. The glutamic acid at 294 has a negative
charge while the lysine at 293 is positively charged. Perhaps these opposite
charged residues provide an internal interaction important for supporting the
activity occurring at this domain. Future mutational analysis to substitute a
negatively charged residue at 293 and a positively charged residue at 294 may
provide more insight in to the interactions in and around 293/294. The tyrosine at
residue 289, glutamine at residue 308, and asparagine at residue 309 are
moderately to highly conserved and polar: substituting a glycine at any two of
these residues leads to a defect in mRNA synthesis.
The body domain region designated for mutagenesis in NPbd3 was
selected for probable interaction with the RdRP based on mini-replicon images
(Coloma et al., 2009). While 294 and 293 may be involved in an internal NP
interaction, we hypothesize that disruption of an essential NP interaction with the
RdRP is the explanation for the RNA defect observed with mutations at 308/309
and 289/309. In support of this, avian influenza virus passaged in human cells
resulted in virus with one amino acid change at residue 309 of NP consistently
paired with specific changes in amino acid 627 of the PB2 subunit of the RdRP
(Danzy et. al., 2014). The double mutant displaying the most significant defect in
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RNA synthesis, 293/294, was used in co-immunopreciptation trials with PB2 (Fig.
24). Since this double mutant may not represent NP interaction with the
polymerase, this experiment will be repeated with inclusion of analysis of
308/309 and 289/309 in order to make a conclusion on the interaction between
our body domain mutants and PB2. Future experiments are focused on obtaining
a better co-immunoprecipitation gel image and running a blue native gel of
vRNPs with small templates to assess vRNP formation directly as in Sanchez et
al., 2014.
I reason that this accessible body domain of NP is an important NP
interaction surface and small molecule inhibitors could block access to this NP
interaction, making this region a viable antiviral target. Indeed, two amino acids in
this NP body domain, 289 and 309, comprise a novel groove implicated in
binding the small molecule inhibitor nucleozin (Kao et. al., 2010). The influenza
A(H1N1)pdm09 strains contained a rare polymorphism at residue 289 (Kao et.
al., 2010). Instead of a tyrosine, these H1N1 strains contain a histidine at amino
acid 289. Tyrosine has a large hydrophobic side chain while histidine has a
smaller and positively charged side chain. This change likely disrupts the
aromatic ring stacking between nucleozin and the tyrosine at 289 (Kao et. al.,
2010). Beyond this, another compound, FA-10 has shown efficacy against the
A(H1N1)pdm09 strains but less activity toward wild-type WSN virus (Kao et. al.,
2010). These studies show that optimization of compounds targeting this domain
could lead to an effective antiviral drug. The work presented here has defined
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this domain with greater clarity, providing evidence that the polar amino acids
289, 308, and 309 provide one target while the charged interaction at 293 and
294 is likely a separate target; perhaps both regions of the domain can be
targeted in a combinational therapeutic approach. This thesis demonstrates that
disruption of this accessible domain should block viral RNA expression and
support additional studies of novel antivirals targeting this conserved NP body
domain.
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CHAPTER EIGHT
MATERIALS AND METHODS

Nucleoprotein Body Domain Mutant Construction
First Step PCR
Polymerase chain reactions (PCR) were carried out in a total of 50 µl with
Thermo Scientific Phusion High-Fidelity DNA polymerase master mix at a 1X
concentration, 50 picomoles (pmol) of each primer, 200 ng of pcDNA NP-FLAG
DNA, and sterile water up to volume.
Table 2. First Step PCR Conditions
Reaction
Reaction A:
Large fragment

Primers
5’ EcoRI NP and 3’
Mutant primer

Reaction B:
Small Fragment

5’ Mutant primer and 3’
Xbalstop1XFLAG
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Cycling Conditions
Initial denaturation: 95 °C for 60
seconds.
Denature: 95 °C for 30 seconds.
Anneal: 60 °C for 40 seconds.
Extend: 72 °C for 150 seconds.
25 cycles.
Same as above.

Table 3. Primer Sequences
Construct
Name
NPbd3

Primer
Name
NP5X289309-F
NP5X289309-R

Y289G
K293G
E294G
Q308G
N309G
Y289G/E294G
K293G/E294G

289G-F
289G-R
293G-F
293G-R
294G-F
294G-R
308G-F
308G-R
309G-F
309G-R
289/294-F
289/294-R
293/294-F
293/294-R

Q308G/N309G
Y289G/Q309G

308/309-F
308/309-R
289/309-F
289/309-R

Restriction
Enzyme End
Primers
EcoRI
XbaI

Primer
Name
5’ EcoRI
NP
3’
Xbalstop1
XFLAG

Sequence (5’ to 3’)
GGCGACTTCGAAGGAGGAGGATACTC
TTTAGTGGGAATAGACCCTTTCAAACT
ACTTGGAGGCAGCCAAG
GCCTCCAAGTAGTTTGAAAGGGTCTAT
TCCCACTAAAGAGTATCCTCCTCCGAA
GTCGCCCCCACTG
GCCAGTGGGGGCGACTTCG
CGAAGTCGCCCCCACTGGC
TACGACTTCGAAGGAGAGGGATACTCT
AGAGTATCCCTCTCCTTCGAAGTCGTA
GACTTCGAAAAAGGAGGATACTC
GAGTATCCTCCTTTTTCGAAGTC
CCTTTCAAACTACTTGGAAACAGC
GCTGTTTCCAAGTAGTTTGAAAGG
CTACTTCAAGGCAGCCAAGTATAC
GTATACTTGGCTGCCTTGAAGTAG
GGGGGCGACTTCGAAAAAGGAGG
CCTCCTTTTTCGAAGTCGCCCCC
TACGACTTCGAAGGAGGAGGATACTCT
TTAGTGGGAATAGACCCTTTCAAACTA
CTTCAAAAC
GTTTTGAAGTAGTTTGAAAGGGTCTATT
CCCACTAAAGAGTATCCTCCTCCTTCG
AAGTCGTA
CCTTTCAAACTACTTGGAGGCAGC
GCTGCCTCCAAGTAGTTTGAAAGG
GGCGACTTCGAAAAAGAGGGATACTCT
TTAGTGGGAATAGACCCTTTCAAACTA
CTTCAAGGC
GCCTTGAAGTAGTTTGAAAGGGTCTAT
TCCCACTAAAGAGTATCCCTCTTTTTCG
AAGTCGCC
Sequence (5’ to 3’)
TATGAATTCATGGCGTCCCAAGGC
GACTCTAGATTAACCGTCATGGTCTTT
GTAGTCCGCCGCATTGTCGTACTCC
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Agarose Gel Extraction. PCR products were run on a 1% agarose gel for
55 minutes at 120 volts (V) and 400 milliamps (mA) to separate any remaining
template DNA from desired product. The QIAquick® Gel Extraction protocol was
followed except for the addition of isopropanol.
Second Step PCR
The next step in the construction required the combination of the small and large
DNA fragments with the addition of restriction enzyme encoded end primers to
obtain the entire desired insert. PCR reactions were carried out in a total of 50 µl
with Thermo Scientific Phusion High-Fidelity DNA polymerase master mix at a 1X
concentration, 100 ng of the large fragment, 70 ng of the small fragment, and 50
pmol of each primer (5’ EcoRI NP and 3’ Xbalstop1XFLAG) which was added
after 10 cycles of PCR. The ratio for the amount of each fragment needed for
PCR was calculated by the following equation: (100ng Large fragment X Size of
Small fragment)/ Size of Large fragment= ng of small fragment for every 100ng
large fragment. The second PCR cycling conditions were as follows: Initial
Denaturation: 95 °C for 60 seconds. Denature: 95 °C for 30 seconds. Anneal: 60
°C for 40 seconds. Extend: 72 °C for 150 seconds. 25 cycles. (Primers added
after 10 cycles).
Confirmation Gel and PCR Purification. Five µl of the 2nd PCR reaction
products, also referred to as the ‘insert’, were loaded on a 1% agarose gel and
run for 55 minutes at 120V and 400mA. The remaining 45 µl of the PCR products
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were purified following the QIAquick® PCR Purification protocol with an elution in
30 µl.
Digest with EcoRI and XbaI. 140 ng of the insert and 500 ng of pcDNA
vector were separately digested with EcoRI (1:20 dilution), XbaI (1:20 dilution),
1X Tango buffer, and water up to volume. The reactions were incubated
overnight at 37 °C. The pcDNA vector was then phosphatase treated with
Antarctic Phosphatase (1:10 dilution) and Antarctic Phosphatase buffer (1:10
dilution) for 30 minutes at 37 °C. The insert and vector were heat inactivated at
80 °C for 20 minutes.
Ligation. Ligation reactions were carried out at the following vector to
insert ratios: 1:1, 1:3, and 1:5. A vector only negative control was included. Each
reaction tube included digested insert and vector DNA (except vector only
control), T4 DNA Ligase (1:10 dilution), T4 DNA Ligase Buffer (1:10 dilution), and
water up to volume. The reaction was incubated overnight at 4 °C.
Transformation. Ligated plasmids were transformed into chemically
competent E. coli cells. In addition to the 1:1, 1:3, 1:5, and vector ligations, a no
DNA control and a positive pUC19 control were also transformed. The
manufacturer’s protocol was followed for TransMax FB5α Competent Cells-10E9
at a smaller volume of 25 µl of cells and 250 µl of S.O.C. medium. The
transformed cells were spread onto Luria-Bertani (LB) agar plates containing
ampicillin (at 100 mg/mL) and incubated over night at 37°C.
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Colony PCR
Candidate colonies on transformation plates were screened for the
plasmid of interest using colony PCR. Individual colonies were picked with a 100
µl pipet tip and used to introduce bacterial cells to a PCR master mix (50 pmol 5’
EcoRI NP and 3’ Xbalstop1XFLAG restriction enzyme end primers, 1X master
mix for Promega Taq polymerase, and water) and also LB AMP liquid media
(grown at 37°C overnight). The following PCR conditions were used: Initial
Denaturation: 95°C for 60 seconds. Denature: 95°C for 30 seconds. Anneal:
60°C for 40 seconds. Extend: 72°C for 150 seconds. 30 cycles. WT-NP was used
as a positive control, while pcDNA vector was used as a negative control. The
PCR products were run on a 1% agarose gel for 55 minutes at 120 V and 400
mA. Candidates demonstrating a similar pattern to WT-NP were miniprepped
using the QIAprep® Spin Miniprep protocol.
Diagnostic Digest
Candidate plasmids were subjected to a diagnostic digest. 400 ng of DNA
was incubated with EcoRI (1:20 dilution), XbaI (1:20 dilution), 1X buffer, and
water at 37°C for one hour. WT-NP was used as a positive control, while pcDNA
vector was used as a negative control. Digested DNA was run on a 1% agarose
gel for 55 minutes at 120 V and 400 mA. Candidates displaying a pattern similar
to WT-NP were sent out for sequencing using flanking and internal primers.
Sequence analysis was carried out using Basic Local Alignment Search Tool
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(BLAST). Plasmids containing the desired mutation were prepared for long term
storage in 15% glycerol and stored at -80 °C.

PB2 C-STREP
Linearization of Template DNA
2,000 ng of pcDNA PB2 was digested with BamHI at a 1:10 dilution at 37
°C for over night in order to linearize the template to be used in the first round of
PCR. The digest was confirmed by migration on a 1% agarose gel for 50 minutes
at 120 V and 400 mA.
Table 4. Primers for PB2 C-STREP Construction
Primer Name
BamHIPB2F
XbalStrepPB2R

Sequence (5’ to 3’)
CGCGGATCCATGGAAAGAATAAAAGAACTACGGAATCT
GATGTCGC
ATATCTAGATTATTTCTCAAATTGTGGATGAGACCAAGC
TGCTGCATTGATGGCCATCCG
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PB2 C-STREP PCR
PCR reactions were carried out in a total of 50 µL with Thermo Scientific
Phusion High-Fidelity DNA polymerase master mix at a 1X concentration, 50
pmol of each primer, 200 ng of linearized pcDNA PB2 DNA, and sterile water up
to volume. PB2 C-STREP cycling conditions were as follows: Initial Denaturation:
95 °C for 60 seconds. Denature: 95 °C for 30 seconds. Anneal: 70 °C for 40
seconds. Extend: 72 °C for 150 seconds. 25 cycles.
PCR product gel extraction, digest, ligation, transformation, colony PCR,
diagnostic digest, and sequencing were performed in the same manner as the
NP plasmid constructs. BamHI and XbaI restriction enzyme sites were utilized for
PB2 C-STREP construction.

Reconstituted Viral Ribonucleoprotein Activity Assay
Cells
293T human embryonic kidney cells were purchased from American Tissue
Culture Collection and maintained at 37 ˚C with 5% CO2 in DMEM with 10% FBS.
Reconstituted Ribonucleoprotein Expression System
In order to reconstitute the influenza RNP expression system, pcDNA
expression vectors of PB1, PB2, PA, and wildtype or mutant NP were transfected
into 293T cells. A pHH21 GFP-MvRNA or pHH21 McRNA expression vector was
used to express the coding RNA. Cellular RNA polymerase I drives expression of
the cRNA or vRNA template from pHH21 encoding plasmids. Cellular RNA
polymerase II drives expression of viral mRNAs from pcDNA3 encoding
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plasmids.
Table 5. Reconstituted Ribonucleoprotein Expression System
Plasmid

Nanograms of DNA (6 well plate)

pcDNA PB1

400

pcDNA WT PB2

400

pcDNA PA

200

pcDNA WT-NP

600

OR No NP (Vector)
OR pcDNA NP mutant
pHH21 GFP MvRNA

400

OR pHH21 McRNA

Transfection
Preparation for transfection began by incubating a lipid-based Trans-IT
reagent (DNA to reagent ratio of 1:3 per plasmid mixture) with 250 µl of
serumfree media (per plasmid mixture) for five minutes at room temperature. The
transfection mixture was then added to the plasmid mixture containing tubes,
flicked to mix, and incubated for 15 minutes at room temperature. The mixture of
plasmids, reagent, and media were then added drop wise into 293T cells at 65
percent confluency. Cells were incubated in a tissue culture incubator for 48
hours.
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Green Fluorescent Protein Visualization
Cells were observed for GFP-M expression 48 hours post transfection.
WT-NP was the positive control while no NP is the negative control. GFP was
visualized with a Nikon Eclipse TS100 (Nikon Intensilight C-HGFI for
fluorescence) inverted microscope and images captured with the Nikon DSQi1Mc camera with NS Elements software.
Cell Collection
Cells were collected and pelleted by centrifugation 48 hours posttransfection. Proteins were isolated through either total protein isolation or
cellular fractionation.
Total Protein Isolation
Cell pellets were resuspended in RIPA Lysis Buffer (25 mM HCl pH 7.6,
150 mM NaCl, 1% deoxycholate, 0.1% SDS) containing protease inhibitors and
lysed using a Fisher Scientific Sonic Dismembrator for 10 pulses at 30%, output
3-4. Proteins were denatured using 1X SDS protein loading dye and boiling for
five minutes. Proteins were separated on a 10% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS PAGE) and transferred to nitrocellulose.
All NP constructs contain a FLAG epitope tag and were detected using antiFLAG. Anti-tubulin was used to confirm even protein loading when evaluating
total protein.
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Cellular Fractionation
Cells were fractionated using 10% NP-40 non-ionic detergent to break
open cellular plasma membrane while keeping the nuclear membranes intact.
Microscopy was used to confirm disrupted plasma membranes and intact nuclei.
The nuclei were pelleted by centrifugation and sonicated for 30 pulses at 30% to
bust the nuclear membrane. Both nuclear and cytoplasmic fractions were
clarified by high-speed centrifugation.
Immunopurification
The nuclear fraction of cells transfected with WT-NP, NPbd3, or No NP
were incubated with Anti-FLAG M2 Affinity Gel agarose beads (Sigma-Aldrich),
incubated overnight at 4°C with rotation, washed five times in RSB (reticulocyte
standard buffer: 10mM Tris HCl pH 7.5, 10mM KCl, 1.5mM MgCl2) + 0.2% NP40, and eluted with 150 ng/ul 3X FLAG peptide (APEXBIO). The elutant was
separated on a 10% SDS PAGE and stained with Coomassie Blue overnight to
check purity.
Gel Shift
Immunopurified proteins were incubated with 20 picomoles of biotinlabeled ssDNA for 20 minutes at room temperature and mixed with 2.5% glycerol
for loading. The protein-DNA samples were run on an 8% TBE non-denaturing
PAGE in 4°C, followed by transfer to nitrocellulose and Western blotting. The
membrane was probed with Streptavadin-HRP (1:3,000) and Pierce ECL
reagents were used to detect the biotin labeled ssDNA.

71

Blue Native Polyacrylamide Gel Electrophoresis
Total protein from WT-NP, NPbd3, or no NP transfected cells were run on
a 6% 1D Blue Native PAGE (Lin et al., 2012) and transferred on to nitrocellulose.
The blot was probed with anti-FLAG to detect WT-NP and NPbd3.
RNA Isolation
Total RNA was isolated with Trizol (Invitrogen), following the
manufacturer’s protocol. RNA concentration and purity of samples was
determined at OD260 and OD280 using a NanoDrop ND1000
Nanospectrophotometer (Thermo Fischer Scientific). Integrity of rRNA was
evaluated on a 1% bleach/1% agarose gel (Aranda et. al., 2012).
RTqPCR
2.5 µg of RNA was DNase treated. 1 µg was reverse transcribed using
Promega AMV reverse transcription system following the manufacturer’s
protocol. 1 µg was used in the negative control reaction, lacking the AMV reverse
transcriptase enzyme to control for DNA contamination. Oligo dT (mRNA) or
vRNA specific primers (vRNA) were used in the RT reaction to produce cDNA.
Real time quantitative PCR using an Applied Biosystems SYBR Select Master
Mix was performed on cDNA with primers targeting the influenza M gene. qPCR
reactions were carried out in triplicate using the AB Step One qPCR machine.
Significance was evaluated through t-test by comparing WT-NP with no NP or
NPbd3 both reporting significance with p-values <0.02.
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Green Fluorescent Protein Fusion Location
Plasmids expressing NP-GFP, NPbd3-GFP, or eGFP were transfected
into 293T cells grown on poly-L-Lysine cover slips. 48 hours post transfection the
cells were washed and fixed using a 1:1 methanol and acetone mixture. The
coverslips were mounted onto glass slides using SouthernBiotech™ DapiFluoromount-G™ Clear Mounting Media, which stains the cell nucleus blue.
Slides were observed on a Nikon ECLIPSE TE2000-U fluorescent microscope
and images were captured with an Andor Clara DR-3446 camera using NISElements AR software. Plasmids NP-GFP and NPbd3-GFP were constructed by
Alan Santana
Testing PB2 C-STREP for Activity
293T cells were transfected following the guidelines in Table 5. GFP
images were captured using Nikon Eclipse TS100 (Nikon Intensilight C-HGFI for
fluorescence) inverted microscope and images captured with the Nikon DSQi1Mc camera with NS Elements software. Total protein was isolated and
separated on a 10% SDS gel and transferred to nitrocellulose. PB2 C-strep was
detected using an anti-STREP antibody (IBA-LifeSciences).
Co-Immunoprecipitation
293T cells were transfected according to Table 6. Cells were collected,
fractionated, and immunopurified as described above. Eluted proteins were run
on a 10% SDS PAGE, transferred to nitrocellulose, and probed with anti-PB2
(GeneTex). The blots were stripped and probed again with anti-FLAG.
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Table 6. Co-Immunoprecipitation Transfection
Sample

NP amount

PB2 amount

WT-NP/PB2

1,000 ng

9,000 ng

293:294/PB2

1,000 ng

9,000 ng

WT-NP only

1,000 ng

0

293:294 only

1,000 ng

0

PB2 only

0

9,000 ng
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